2 weeks Ago By ABMN Staff
Townsquare Capital LLC increased its stake in Edwards Lifesciences Co. ( NYSE:EW – Free Report ) by 24.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 6,501 shares of the medical research company’s stock after purchasing an additional 1,293 shares during the quarter. Townsquare Capital LLC’s holdings in Edwards Lifesciences were worth $481,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors and hedge funds have also recently bought and sold shares of EW.
Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 10.4% during the fourth quarter.
Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 5.
3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.
9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the period. Fisher Asset Management LLC grew its position in Edwards Lifesciences by 7.
7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. Finally, Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $610,895,000.
Institutional investors and hedge funds own 79.46% of the company’s stock. Insider Activity In other Edwards Lifesciences news, Director Steven R.
Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.
38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24.
This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink .
Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.
76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.
36. The trade was a 26.91 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Over the last ninety days, insiders have sold 71,853 shares of company stock worth $5,163,062. Company insiders own 1.
29% of the company’s stock. Wall Street Analysts Forecast Growth Check Out Our Latest Analysis on Edwards Lifesciences Edwards Lifesciences Price Performance NYSE:EW opened at $71.56 on Monday.
The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.
89. The stock has a market cap of $42.07 billion, a P/E ratio of 10.
27, a PEG ratio of 4.82 and a beta of 1.15.
The company has a fifty day moving average price of $71.31 and a 200 day moving average price of $70.92.
Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.
25. Edwards Lifesciences ( NYSE:EW – Get Free Report ) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.
59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04.
Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.
Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.
Edwards Lifesciences Profile ( Free Report ) Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. Read More Want to see what other hedge funds are holding EW? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. ( NYSE:EW – Free Report ). Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
